MedDataX Logo

Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

NCT ID: NCT01238809

Last Updated: 2011-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Total Enrollment

7300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France

NCT01211652

Healthy
COMPLETED

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

NCT00681759

Cardiovascular Disease
COMPLETED

Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2

NCT00691743

Upper-GI Symptoms
COMPLETED

First Approach for Aspirin Misuse Objective Screening

NCT02997436

Peripheral Arterial Disease
COMPLETED NA

The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)

NCT00250380

Coronary Disease Cerebral Infarction Ischemic Attack, Transient
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Self-administered Questionnaire to Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* French people \> 60 years old, part of Kantar Health Access Sant� panel
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mrs Genevieve BONNELYE

Role: PRINCIPAL_INVESTIGATOR

KantarHealth - France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CFR-DUM-2010/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy
NCT01888575 COMPLETED
EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom ("ENgAGE - UK"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK
NCT03743883 COMPLETED
The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users
NCT01814943 COMPLETED
Risk of Uncomplicated Peptic Ulcer in the General Population
NCT01888588 COMPLETED
Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia
NCT01104441 COMPLETED
Duration of Platelet Inhibition by Aspirin
NCT00671021 COMPLETED
Aspirin in Reducing Events in the Elderly
NCT01038583 UNKNOWN
Aspirin Resistance in Coronary Artery Disease
NCT00753935 COMPLETED EARLY_PHASE1
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
NCT04586972 COMPLETED
Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)
NCT00981032 COMPLETED NA
The Effect of a Probiotic Strain on Aspirin-induced GI Damage.
NCT03228589 COMPLETED PHASE2
Compliance in the Physicians' Health Study
NCT00005404 COMPLETED
Aspirin Responsiveness in Women With Coronary Artery Disease
NCT01406990 COMPLETED
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
NCT00222261 COMPLETED PHASE4
ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
NCT04912505 COMPLETED PHASE2
TIME ASPIRIN: Chronotherapy With Aspirin for Reduction of Cardiovascular Disease
NCT04132791 TERMINATED NA
Timed Aspirin Chronobiome Study
NCT03590821 NOT_YET_RECRUITING EARLY_PHASE1
Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy
NCT05553717 UNKNOWN NA
Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease
NCT04217447 TERMINATED PHASE3
Japanese Primary Prevention Project With Aspirin
NCT00225849 UNKNOWN PHASE4
Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk
NCT02960126 UNKNOWN PHASE3
Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg
NCT01669824 COMPLETED
An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel
NCT01210339 COMPLETED PHASE1
Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease
NCT03757156 UNKNOWN NA
Appropriateness of Aspirin Use in Medical Outpatients
NCT03387384 UNKNOWN